Boehringer Ingelheim International Gmbh

Elbion Gmbh

Wyeth

Asta Medica, Aktiengesellschaft

Elbion Ag

Hans Stange

Norbert Höfgen

Barbara Langen

Ute Egerland

Hans-Joachim Lankau

Rudolf Schindler

Christian Grunwald

Michael Sotirios Malamas

Riccardo Giovannini

Bernhard Kutscher

Sara Frattini

Peter Emig

Chris Rundfeldt

Rita Dost

Alfred Olbrich

Barbara Bertani

James Joseph Erdei

Karl-Friedrich Landgraf

Helge Hartenhauer

Hans-Joachim Jänsch

Jürgen Schäfer

Yike Ni

Thomas Pfeifer

Giustino Di Antonio

Ure Egerland

Norbert Hoefgen

Siegfried Pauluhn

The invention relates to (1,2,4)triazolo[4,3-a]quinoxaline derivatives which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases.

(1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases

The compounds are of the class of pyrido[3,2-e][1,2,4]-tiazolo[4,3-a]pyrazines, useful in the treatment of central nervous system disorders. A species illustrative of members of the class is the following: 

Substituted pyrido[3,2-E][1,2,4]-triazolo[4,3-A]pyrazines for the treatment of central nervous system disorders

The invention relates to imidazo[1,5-a]quinoxaline derivatives having Formula IIa: to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10 (PDE10), as active compounds for treating central nervous system diseases of mammals, including humans.

Substituted imidazo[1,5-a]quinoxalines useful as inhibitors of phosphodiesterase 10 for the treatment of neurological and other disorders

The invention relates to pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10, as active compounds for treating diseases of mammals including a human which can be influenced by using the compounds according to the invention to inhibit phosphodiesterase 10 activity in the central nervous system. More particularly, the invention relates to the treatment of neurologic and psychiatric disorders, for example psychosis and disorders comprising cognitive deficits as symptoms.

Pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them

The invention relates to a process for preparing hydroxyindolylglyoxylamides in high yields and particularly pure form.

Process for preparing high-purity hydroxyindolylglyoxylamides

A process for preparation of pure flupertine maleate and the pure A crystalline form of flupertine maleate by the use of water soluble alcohols during synthesis and/or purification.

Process for the preparation of pure flupirtine maleate and its A

Growing community of inventors

Riesa, Germany

Hans Stange